Contineum Therapeutics (CTNM) Income towards Parent Company (2023 - 2026)

Contineum Therapeutics' Income towards Parent Company history runs 4 years deep, the most recent figure standing at -$14.4 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 9.21% year-over-year to -$14.4 million; the TTM figure through Mar 2026 stood at -$58.4 million (down 17.41% YoY), while the FY2025 annual figure was -$59.8 million, down 41.54% from the prior year.
• Income towards Parent Company was -$14.4 million for Q1 2026 at Contineum Therapeutics, up from -$15.1 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $41.6 million in Q2 2023 to a low of -$15.9 million in Q2 2025.
• Historically, Income towards Parent Company has averaged -$7.2 million across 4 years, with a median of -$10.3 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Income towards Parent Company sank 121.66% in 2024, then increased 9.21% in 2026.
• A 4-year view of Income towards Parent Company shows it stood at -$7.8 million in 2023, then slumped by 87.48% to -$14.6 million in 2024, then slipped by 3.71% to -$15.1 million in 2025, then gained by 4.67% to -$14.4 million in 2026.
• The last three Income towards Parent Company figures came in at -$14.4 million (Q1 2026), -$15.1 million (Q4 2025), and -$13.0 million (Q3 2025), per Business Quant data.